Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

NCT06048705 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to a change in GSK's R\&D priorities.

Conditions

Neoplasms

Interventions

DRUG: GSK3901961
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Adaptimmune